1619923-52-2

Usage

Contains a piperazine ring

A heterocyclic compound with a six-membered ring containing two nitrogen atoms.

Multiple phenyl rings

Aromatic hydrocarbon groups consisting of a six-membered ring with alternating single and double carbon-carbon bonds.

Multiple pyrrol rings

A heterocyclic compound with a five-membered ring containing one nitrogen atom and four carbon atoms.

Chlorophenyl functional group

A phenyl ring with a chlorine atom attached.

Isopropyl functional group

A branched alkyl group with two carbon atoms attached to a central carbon atom.

Methyl functional group

A univalent alkyl group consisting of one carbon atom and three hydrogen atoms.

Methylsulfonyl functional group

A sulfur-containing functional group with a methanesulfonyl group attached to a sulfur atom.

Nitro functional group

A functional group containing a nitrogen-oxygen double bond and a single oxygen atom attached to a nitrogen atom.

Fluoro functional group

A halogen atom, specifically fluorine, attached to a carbon atom.

Potential pharmaceutical or research chemical

Indicates that the compound may have biological activity and could be used as a therapeutic agent for various conditions.

Further study and testing required

The specific properties and potential uses of the compound would need to be determined through additional research and experimentation.

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 43189-20-4 methyl (±)-2-amino-2-(4-chlorophenyl)acetate 
• 6212-33-5 2-(4-Chlorophenyl)glycine 
• 20277-69-4 sodium methansulfinate 
• 2386-57-4 methanesulfonic acid sodium salt 
• 62518-43-8 proline sodium salt 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 1619923-36-2 (R)-3-(1-(3-(4-(N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)sulfamoyl)-2-(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)piperidine-4-carbonyloxy)propylphosphonic acid 
• 1619923-32-8 (R)-1-(3-((4-(N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)sulfamoyl)-2-((trifluoromethyl)sulfonyl)phenyl)amino)-4-(phenylthio)butyl)piperidine-4-carboxylic acid 
• 1619923-53-3 N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)-4-fluoro-3-(trifluoromethylsulfonyl)benzenesulfonamide 
• 1619923-27-1 (R)-(1-(3-(4-(N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl) sulfamoyl)-2(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)piperidin-4-yloxy)methyl dihydrogen phosphate 
• 1619923-39-5 (R)-1-(3-(4-(N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)sulfamoyl)-2-(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)-4-methylpiperidine-4-carboxylic acid 

Relevant academic research and scientific papers

Process for preparing sulfonamide compounds

The invention relates to a process for preparing sulfonamide compounds. The sulfonamide compound is an inhibitor of Bcl-2/Bcl-xL and is prepared from a compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorphenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrole-3-yl

PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS

Provided are a process for preparing a sulfonamide compound which is an inhibitor of Bcl-2/Bcl-xL, including the compound (3R) -1- (3- (4- (4- (4- (3- (2- (4-chlorophenyl) -1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl) -5-fluorophenyl) piperazine

METHOD FOR PREPARING SULFONAMIDES DRUGS

Provided is a method for preparing sulfonamides which are inhibitors of Bcl-2/ Bcl-xL, comprising the compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl) -1-isopropyl-4-methylsulfonyl-5-methyI-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yI)-phenylam inosulf

Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer

This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold. The phospholidine compounds can include a P-phenyl phospholidine moiety which is substituted with an N-aryl or N-heteroaryl group. The P-phenyl phospholidine moiety can be optionally substituted at phosphorus with thio (═S) instead of oxo (═O). A second heteroatom attached to phosphorus can be cyclically linked to the N-substituted nitrogen atom of the phospholidine that is attached to the phosphorus to provide, together with the phosphorus atom through which they are connected, a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety a favorable binding conformation can be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis. Selected compounds promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.